Corium International (NASDAQ:CORI)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Monday. They currently have a $13.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 39.78% from the stock’s current price.
The analysts wrote, “Our $13 12-month target is based on a DCF reflecting an 11.5% WACC discount and 1.5% terminal growth beyond fiscal 2026. Our model only explicitly includes the base-business, and U.S. partner revenue for the donepezil patch (launch 1Q20) and Twirla (launch calendar 2H19, but not in the stock now after partner setbacks). The donepezil patch has IP to 2037 and Twirla has issued patents to 2028.””
CORI has been the subject of a number of other research reports. Zacks Investment Research cut Corium International from a “buy” rating to a “sell” rating in a report on Monday, April 16th. ValuEngine raised Corium International from a “hold” rating to a “buy” rating in a report on Friday. BidaskClub lowered Corium International from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $14.00 price objective on shares of Corium International in a research report on Friday. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. Corium International currently has a consensus rating of “Hold” and a consensus target price of $12.80.
Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04. Corium International had a negative return on equity of 298.48% and a negative net margin of 155.21%. The company had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $6.72 million. research analysts forecast that Corium International will post -1.59 earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. MetLife Investment Advisors LLC bought a new stake in Corium International during the 4th quarter worth $123,000. DekaBank Deutsche Girozentrale bought a new stake in Corium International during the 1st quarter worth $167,000. Engineers Gate Manager LP bought a new stake in Corium International during the 2nd quarter worth $215,000. Goldman Sachs Group Inc. grew its position in Corium International by 126.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 18,416 shares during the last quarter. Finally, Two Sigma Advisers LP bought a new stake in shares of Corium International in the 4th quarter valued at about $317,000. Institutional investors and hedge funds own 95.26% of the company’s stock.
Corium International Company Profile
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Featured Article: Relative Strength Index
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.